日前,江苏省医保局发布《关于公布江苏省第五轮药品集中带量采购补充中选产品的通知(四)》。通知附件显示,石家庄四药以34.8元/盒申报的阿昔莫司胶囊,通过补充中选方式入围江苏省第五轮药品集采。值得一提的是,江苏省在此前公告中明确,补充中选产品并不参与集采分量。石家庄四药此举并非个案,针对第五轮药品集采,江苏省此前已公布过三批补充中选结果,拜耳的注射用重组人凝血因子Ⅷ、石药集团百克生物的聚乙二醇化重组...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.